The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients

Clinical Therapeutics

Volumn 22, Issue SUPPL. B, 2000, Pages

  Salm, Paul ^a,b   Taylor, Paul J ^a   Pillans, Peter I ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

High performance liquid chromatography mass spectrometry; Microparticle enzyme immunoassay; Sirolimus; Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN A; RAPAMYCIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MICROPARTICLE ENZYME IMMUNOASSAY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY;

EID: 0034080768     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)89024-4     Document Type: Article

References (33)

1. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic: I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot. 1975;28:722-726.
2. Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic: II. Fermentation, isolation and characterization. J Antibiot. 1975;28:727-732.
3. Sehgal SN. Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit. 1995;17:660-665.
4. Sehgal SN. Rapamune® (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335-340.
5. Stepkowski SM, Napoli KL, Wang M, et al. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation. 1996;62;986-994.
6. Kahan BD, Gibbons S, Tejpal N, et al. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation. 1991;51:232-239.
7. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation. 1998;66:1040-1046.
8. Brattström C, Wilczek H, Tydén G, et al. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation. 1998;65:1272-1274.
9. Groth CG, Bäckman L, Morales J-M, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation. 1999;67:1036-1042.
10. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol. 1997;37:405-415.
11. Yatscoff RW, Le Gatt D, Keenan R, Chackowsky P. Blood distribution of rapamycin. Transplantation. 1993;56:1202-1206.
12. Christians U, Sattler M, Schiebel HM, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos. 1992; 20:186-191.
13. Kahan BD, Napoli KL. Role of therapeutic drug monitoring of rapamycin. Transplant Proc. 1988;30:2189-2191.
14. Yatscoff RW, Boeckx R, Holt DW, et al. Consensus guidelines for therapeutic drug monitoring of rapamycin: Report of the consensus panel. Ther Drug Monit. 1995; 17:676-680.
15. Streit F, Christians U, Schiebel HM, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. 1996;42:1417-1425.
16. Taylor PJ, Johnson AG. Quantitative analysis of sirolimus (rapamycin) in blood by high performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Biomed Appl. 1998;718: 251-257.
17. Kirchner GI, Vidal C, Jacobsen W, et al. Simultaneous on-line extraction and analysis of sirolimus (rapamycin) and cyclosporin in blood by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Appl. 1999;721: 285-294.
18. Yatscoff RW, Faraci C, Bolingbroke P. Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography. Ther Drug Monit. 1992;14:138-141.
19. Napoli KL, Kahan BD. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. J Chromatogr B Biomed Appl. 1994;654: 111-120.
20. Napoli KL, Kahan BD. High-performance liquid chromatography of rapamycin. Clin Chem. 1991;37:294-295.
21. Svensson J-O, Brattström C, Säwe J. Determination of rapamycin in whole blood by HPLC. Ther Drug Monit. 1997;19:112-116.
22. Kahan BD. Emerging strategies for the clinical application of rapamycin. Clin Biochem. 1998;31:341-344.
23. Kahan BD, Murgia MG, Slaton J, Napoli K. Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Ther Drug Monit. 1995;17:672-675.
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatininc. Nephron. 1976;16:31-41.
25. Abbott IMx® clinical brochure (revision 2.0). Abbott Park, Ill: Abbott Laboratories; 1997.
26. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;i:307-310.
27. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci. 1992;81:309-312.
28. Oellerich M, Armstrong VW, Schütz E, Shaw LM. Therapeutic drug monitoring of cyclosporin and tacrolimus. Clin Biochem. 1998;31:309-316.
29. Bowers LD. Analytical goals in therapeutic drug monitoring. Clin Chem. 1998; 44:375-380.
30. Shaw LM, Annesley TM, Kaplan B, Brayman KL. Analytical requirements for immunosuppressive drugs in clinical trials. Ther Drug Monit. 1995;17:577-583.
31. Salm P, Taylor PJ, Pillans PI. Analytical performance of microparticle enzyme immunoassay and HPLC-tandem mass spectrometry in the determination of sirolimus in whole blood. Technical Brief. Clin Chem. 1999;45:2278-2280.
32. Blonski DR, Bergmann E, Luczkiw J, et al. Clinical studies on IMx® sirolimus, a semi-automated whole blood assay. Clin Chem. 1998;44:92. Abstract.
33. Holt DW, Jones K, Horwatt R, Hicks D. An immunoassay for the measurement of sirolimus. Clin Chem. 1998;44:94. Abstract.